These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 11782036)

  • 1. On the use of Cox regression in the presence of an irregularly observed time-dependent covariate.
    de Bruijne MH; le Cessie S; Kluin-Nelemans HC; van Houwelingen HC
    Stat Med; 2001 Dec; 20(24):3817-29. PubMed ID: 11782036
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hydroxyurea versus busulphan for chronic myeloid leukaemia: an individual patient data meta-analysis of three randomized trials. Chronic myeloid leukemia trialists' collaborative group.
    Br J Haematol; 2000 Sep; 110(3):573-6. PubMed ID: 10997966
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dunnett-type inference in the frailty Cox model with covariates.
    Herberich E; Hothorn T
    Stat Med; 2012 Jan; 31(1):45-55. PubMed ID: 22095770
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Regression with bounded outcome score: evaluation of power by bootstrap and simulation in a chronic myelogenous leukaemia clinical trial.
    Tsodikov A; Hasenclever D; Loeffler M
    Stat Med; 1998 Sep; 17(17):1909-22. PubMed ID: 9777686
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Chronic myeloid leukemia in the elderly: long-term results from randomized trials with interferon alpha.
    Berger U; Engelich G; Maywald O; Pfirrmann M; Hochhaus A; Reiter A; Metzgeroth G; Gnad U; Hasford J; Heinze B; Heimpel H; Hossfeld DK; Kolb HJ; Löffler H; Pralle H; Queisser W; Hehlmann R;
    Leukemia; 2003 Sep; 17(9):1820-6. PubMed ID: 12970782
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Chronic myeloid leukaemia with marked thrombocytosis in a patient with thalassaemia major: complete haematological remission under the combination of hydroxyurea and anagrelide.
    Voskaridou E; Terpos E; Komninaka V; Eftyhiadis E; Mantzourani M; Loukopoulos D
    Br J Haematol; 2002 Jan; 116(1):155-7. PubMed ID: 11841409
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Chronic myeloid leukemia.
    Singhal N; Bapsy PP; Babu KG; George J
    J Assoc Physicians India; 2004 May; 52():410-6. PubMed ID: 15656033
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cyclic oscillations of leucocyte counts in chronic myeloid leukaemia.
    Malhotra OP; Salam SR
    Postgrad Med J; 1991 Jan; 67(783):87-9. PubMed ID: 2057439
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hydroxyurea induced leg ulcers.
    Abhyankar D; Shende C; Saikia T; Advani SH
    J Assoc Physicians India; 2000 Sep; 48(9):926-7. PubMed ID: 11198798
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Outcome prediction by the transcript level of BCR-ABL at 3 months in patients with chronic myeloid leukemia treated with imatinib--a single institution historical experience.
    Yin XF; Ma QL; Mu QT; Shao L; Wang SS; Meng HT; Xu WL; Wang YG; Chen ZM; Chen FF; Jin J
    Leuk Res; 2014 Oct; 38(10):1191-8. PubMed ID: 25115808
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Myositis caused by hydroxyurea in a patient with chronic myelogenous leukemia].
    Ikeda K; Mita M; Ishibashi T; Shichishima T; Maruyama Y
    Rinsho Ketsueki; 1998 Sep; 39(9):676-9. PubMed ID: 9796402
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antitumor effects of celecoxib on K562 leukemia cells are mediated by cell-cycle arrest, caspase-3 activation, and downregulation of Cox-2 expression and are synergistic with hydroxyurea or imatinib.
    Zhang GS; Liu DS; Dai CW; Li RJ
    Am J Hematol; 2006 Apr; 81(4):242-55. PubMed ID: 16550520
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The German CML study, comparison of busulfan vs. hydroxyurea vs. interferon alpha and establishment of prognostic score 1.
    Hehlmann R; Heimpel H; Kolb HJ; Heinze B; Hochhaus A; Griesshammer M; Pralle H; Queisser WP; Essers U; Falge C
    Leuk Lymphoma; 1993; 11 Suppl 1():159-68. PubMed ID: 8251890
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An accelerrated-phase CML patient with e19a2 junction of BCR/ABL gene - the first case of transplanted CML with micro bcr.
    Polák J; Koza V; Cetkovský P; Haskovec C
    Bone Marrow Transplant; 2000 May; 25(10):1109-10. PubMed ID: 10828875
    [No Abstract]   [Full Text] [Related]  

  • 15. [Tyrosine kinase inhibitors for the treatment of CML].
    Heim D
    Ther Umsch; 2006 Apr; 63(4):249-54. PubMed ID: 16689455
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Achievement of a complete cytogenetic response with hydroxyurea in a patient with chronic myelogenous leukemia.
    Tanaka M; Yamazaki Y; Kondo E; Hattori M; Tsushita K; Utsumi M
    Leuk Res; 1997 May; 21(5):465-8. PubMed ID: 9225076
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Clinical analysis about the management and the perinatal outcomes of pregnancy with chronic myeloid leukemia].
    Wang DP; Liang MY; Zhang XH; Wang SM
    Zhonghua Fu Chan Ke Za Zhi; 2010 Oct; 45(10):735-9. PubMed ID: 21176552
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Applying the Cox proportional hazards model when the change time of a binary time-varying covariate is interval censored.
    Goggins WB; Finkelstein DM; Zaslavsky AM
    Biometrics; 1999 Jun; 55(2):445-51. PubMed ID: 11318198
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The pros and cons of new prognostic eutos score for chronic myeloid leukemia patients.
    Breccia M; Alimena G
    Leuk Res; 2013 Nov; 37(11):1436-7. PubMed ID: 24054718
    [No Abstract]   [Full Text] [Related]  

  • 20. Comparative analysis of the impact of risk profile and of drug therapy on survival in CML using Sokal's index and a new score. German chronic myeloid leukaemia (CML)-Study Group.
    Hehlmann R; Ansari H; Hasford J; Heimpel H; Hossfeld DK; Kolb HJ; Löffler H; Pralle H; Queisser W; Reiter A; Hochhaus A
    Br J Haematol; 1997 Apr; 97(1):76-85. PubMed ID: 9136944
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.